Arthur P. Staddon
About
Arthur P. Staddon is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Rheumatology.
According to data from OpenAlex, Arthur P. Staddon has authored 67 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Pulmonary and Respiratory Medicine, 29 papers in Oncology and 16 papers in Rheumatology. Recurrent topics in Arthur P. Staddon's work include Sarcoma Diagnosis and Treatment (43 papers), Bone Tumor Diagnosis and Treatments (14 papers) and Vascular Tumors and Angiosarcomas (10 papers). Arthur P. Staddon is often cited by papers focused on Sarcoma Diagnosis and Treatment (43 papers), Bone Tumor Diagnosis and Treatments (14 papers) and Vascular Tumors and Angiosarcomas (10 papers). Arthur P. Staddon collaborates with scholars based in United States, France and United Kingdom. Arthur P. Staddon's co-authors include Sant P. Chawla, Jean‐Yves Blay, Scott M. Schuetze, Keith M. Skubitz, Robert M. Henshaw, David M. Thomas, George D. Demetri, Kristen N. Ganjoo, Mohammed Milhem and Shreyaskumar Patel and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The Lancet Oncology.
In The Last Decade
Arthur P. Staddon
64 papers receiving 3.5k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Arthur P. Staddon United States | 29 | 2.4k | 1.4k | 1.1k | 652 | 621 | 67 | 3.5k | ||
| Alessandro Comandone Italy | 25 | 2.3k 0.9× | 1.4k 1.0× | 913 0.8× | 420 0.6× | 131 0.2× | 103 | 3.0k | ||
| Federica Grosso Italy | 33 | 3.0k 1.2× | 1.8k 1.2× | 633 0.6× | 642 1.0× | 128 0.2× | 158 | 4.4k | ||
| Adrián Mariño‐Enríquez United States | 35 | 2.2k 0.9× | 861 0.6× | 1.1k 1.0× | 734 1.1× | 130 0.2× | 94 | 3.6k | ||
| Philippe Terrier France | 31 | 2.2k 0.9× | 963 0.7× | 1.2k 1.1× | 519 0.8× | 120 0.2× | 60 | 3.3k | ||
| Mary Louise Keohan United States | 34 | 2.8k 1.1× | 2.2k 1.5× | 718 0.6× | 673 1.0× | 106 0.2× | 105 | 4.4k | ||
| Flavio Crippa Italy | 30 | 1.1k 0.4× | 1.1k 0.8× | 508 0.4× | 340 0.5× | 309 0.5× | 124 | 3.2k | ||
| Brian L. Samuels United States | 29 | 2.2k 0.9× | 1.7k 1.2× | 526 0.5× | 497 0.8× | 114 0.2× | 74 | 3.4k | ||
| Rossella Bertulli Italy | 25 | 3.9k 1.6× | 1.5k 1.1× | 1.5k 1.3× | 428 0.7× | 183 0.3× | 82 | 5.1k | ||
| Dominique Ranchère‐Vince France | 32 | 3.0k 1.2× | 1.4k 1.0× | 1.2k 1.1× | 596 0.9× | 100 0.2× | 89 | 3.9k | ||
| Rick L. Haas Netherlands | 33 | 2.5k 1.0× | 1.5k 1.0× | 868 0.8× | 265 0.4× | 108 0.2× | 114 | 3.4k |
Countries citing papers authored by Arthur P. Staddon
Since
Specialization
Citations
This map shows the geographic impact of Arthur P. Staddon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arthur P. Staddon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arthur P. Staddon more than expected).
Fields of papers citing papers by Arthur P. Staddon
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Arthur P. Staddon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arthur P. Staddon. The network helps show where Arthur P. Staddon may publish in the future.
Co-authorship network of co-authors of Arthur P. Staddon
This figure shows the co-authorship network connecting the top 25 collaborators of Arthur P. Staddon. A scholar is included among the top collaborators of Arthur P. Staddon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arthur P. Staddon. Arthur P. Staddon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Baumann, Brian C., Karen De Amorim Bernstein, Thomas F. DeLaney, et al.. (2020). Multi‐institutional analysis of stereotactic body radiotherapy for sarcoma pulmonary metastases: High rates of local control with favorable toxicity. Journal of Surgical Oncology. 122(5). 877–883.
2.
Chow, Warren, Paul Frankel, Dejka M. Araujo, et al.. (2019). Results of a prospective phase 2 study of pazopanib in patients with surgically unresectable or metastatic chondrosarcoma. Cancer. 126(1). 105–111.
3.
Staddon, Arthur P., et al.. (2017). Sertoli-Leydig Cell Tumor with Concurrent Rhabdomyosarcoma: Three Case Reports and a Review of the Literature. Case Reports in Medicine. 2017. 1–6.
4.
Hensley, Martee L., Shreyaskumar Patel, Margaret von Mehren, et al.. (2017). Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial. Gynecologic Oncology. 146(3). 531–537.
5.
Demetri, George D., Margaret von Mehren, Robin L. Jones, et al.. (2015). Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. Journal of Clinical Oncology. 34(8). 786–793.
6.
Jönsson, Linus, Nahila Justo, Thomas Burke, et al.. (2015). Cost of treatment in patients with metastatic soft tissue sarcoma who respond favourably to chemotherpy. The SArcoma treatment and Burden of Illness in North America and Europe (SABINE) study. European Journal of Cancer Care. 25(3). 466–477.
7.
Martín‐Broto, Javier, Charles S. Cleeland, Paul Glare, et al.. (2014). Effects of denosumab on pain and analgesic use in giant cell tumor of bone: Interim results from a phase II study. Acta Oncologica. 53(9). 1173–1179.
8.
Machiels, Jean Pascal, Arthur P. Staddon, Charles E. Phelps, et al.. (2014). Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies. Cancer Chemotherapy and Pharmacology. 74(4). 729–737.
9.
Chawla, Sant P., Robert M. Henshaw, Leanne L. Seeger, et al.. (2013). Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. The Lancet Oncology. 14(9). 901–908.
10.
Chawla, Sant P., et al.. (2013). Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide. BMC Cancer. 13(1). 121–121.
11.
Baird, Kristin, Denise K. Reinke, Joseph G. Pressey, et al.. (2013). A randomized, double-blinded, placebo-controlled, multi-institutional, cross-over, phase II.5 study of saracatinib (AZD0530), a selective Src kinase inhibitor, in patients with recurrent osteosarcoma localized to the lung.. Journal of Clinical Oncology. 31(15_suppl). TPS10591–TPS10591.
12.
Leahy, Michael, Xavier García del Muro, Peter Reichardt, et al.. (2012). Chemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma. The SArcoma treatment and Burden of Illness in North America and Europe (SABINE) study. Annals of Oncology. 23(10). 2763–2770.
13.
Marréaud, Sandrine, Winette T.A. van der Graaf, Jean‐Yves Blay, et al.. (2012). Global differences in chemotherapeutic regimens of soft tissue sarcoma (STS): Results of PALETTE, an EORTC 62072/GSK VEG110727 global network phase III trial of pazopanib versus placebo.. Journal of Clinical Oncology. 30(15_suppl). 10067–10067.
14.
Predina, Jarrod D., Matthew Puc, Meredith Bergey, et al.. (2011). Improved Survival after Pulmonary Metastasectomy for Soft Tissue Sarcoma. Journal of Thoracic Oncology. 6(5). 913–919.
15.
Thertulien, Raymond, G. Manikhas, Luc Dirix, et al.. (2011). Effect of trabectedin on the QT interval in patients with advanced solid tumor malignancies. Cancer Chemotherapy and Pharmacology. 69(2). 341–350.
16.
Moretti, Vincent M., Eileen A. Crawford, Arthur P. Staddon, Richard D. Lackman, & Christian M. Ogilvie. (2010). Early Outcomes for Malignant Peripheral Nerve Sheath Tumor Treated With Chemotherapy. American Journal of Clinical Oncology. 34(4). 417–421.
17.
Schuetze, Scott M., Edwin Choy, Brian L. Samuels, et al.. (2010). Results of a Sarcoma Alliance for Research through Collaboration (SARC) phase II trial of dasatinib in previously treated, high-grade, advanced sarcoma.. Journal of Clinical Oncology. 28(15_suppl). 10009–10009.
18.
Staddon, Arthur P., Eileen A. Crawford, Lee Hartner, Richard D. Lackman, & Christian M. Ogilvie. (2008). Treatment of metastatic sarcomatoid carcinoma with doxorubicin and ifosfamide. Journal of Clinical Oncology. 26(15_suppl). 21518–21518.
19.
Staddon, Arthur P., et al.. (2006). Tolerability of pegylated liposomal doxorubicin 20 mg/m2 every 2 weeks in the management of solid or hematologic malignancies. Journal of Clinical Oncology. 24(18_suppl). 18500–18500.
20.
Fox, Edward, et al.. (2005). The effects of ciprofloxacin and paclitaxel on metastatic and recurrent chondrosarcoma. Community Oncology. 2(6). 516–522.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Alessandro Comandone Breakdown of academic impact, for papers by Federica Grosso Breakdown of academic impact, for papers by Adrián Mariño‐Enríquez Breakdown of academic impact, for papers by Philippe Terrier Breakdown of academic impact, for papers by Mary Louise Keohan Breakdown of academic impact, for papers by Flavio Crippa Breakdown of academic impact, for papers by Brian L. Samuels Breakdown of academic impact, for papers by Rossella Bertulli Breakdown of academic impact, for papers by Dominique Ranchère‐Vince Breakdown of academic impact, for papers by Rick L. Haas